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Abstract: In the last 20 years, dendritic cells (DCs) have been largely used as a platform for therapeutic
vaccination in cancer patients. However, despite its proven safety and ability to induce cancer specific
immune responses, the clinical benefits of DC-based immunotherapy are currently very limited.
Thus, novel approaches are still needed to boost its efficacy. Our group recently showed that squaric
acid treatment of antigens is an important adjuvant that can increase vaccine-induced downstream
immune responses and therapeutic outcomes. Here we further improved this dendritic cell vaccine
formulation by developing a new method for differentiating and maturing DCs from their bone
marrow precursors. Our data demonstrate that bone marrow-derived DCs differentiated with
GM-CSF and IL-15 and matured with a maturation cocktail in two steps present a more mature
and immunogenic phenotype, compared to standard DC preparations. Further suppression of the
prostaglandin E2 pathway achieved even more immunogenic DC phenotypes. This vaccine was more
potent at delaying tumor growth, improved animal survival and induced a more immunogenic and
Th1-skewed T cell response in an ovarian cancer mouse model. These promising results support
future efforts for the clinical translation of this approach.
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1. Introduction
Ovarian cancer is one of the most severe gynecologic cancers and has a very high mortality rate.
Over 230,000 women are diagnosed with ovarian cancer worldwide each year, and about 140,000
women die from the disease [1]. Unfortunately, 85% of all ovarian cancer cases are detected only at a
late-stage, with a 5-year survival rate of 39% [1].
Previous evidence demonstrated that despite the relatively low mutational burden in ovarian
carcinoma compared to other cancer types [2,3], tumor infiltrating T lymphocytes naturally occur in
>50% of ovarian cancer patients, a feature that well correlates with improved clinical outcomes [4].
Furthermore, T cells isolated from ovarian cancer patients are able to recognize tumor-associated
antigens (TAAs) and exhibit tumor-specific cytotoxic activity in vitro [5]. Based on this collective
evidence, subsequent clinical studies employed dendritic cell (DC) based cancer vaccines in an attempt
to stimulate and sustain a tumor specific T cell response. These studies [6] (and others for other
types of cancer) [7] importantly demonstrated the clinical safety and feasibility of DC based vaccines.
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However, despite the crucial role of DCs in stimulating and orchestrating both innate and adoptive
immune responses [8], the objective response rates of clinical studies with DC cancer vaccines rarely
exceeded 15% [9,10]. Hence, it is generally believed that we have not yet harnessed the true potential of
DC-based anti-cancer vaccines and novel strategies should be developed to improve current therapeutic
outcomes [11].
Two aspects of DC immunobiology are particularly crucial in designing a DC vaccine: the antigen
source and the differentiation and maturation stimuli engaged. Our group previously focused
on optimizing whole tumor cell lysate (WTL) preparation identifying in particular HOCl [12,13]
and squaric acid [14] as two potent treatments able to increase the immunogenicity of the WTL
antigen source. In this study we focused instead on the optimization of the differentiation and
maturation stimuli applied respectively to DC precursors and immature DCs in order to reach their
fully immunogenic potential. The most widely accepted protocol to prepare DCs for clinical cancer
vaccination involves the differentiation of DCs from their isolated precursors (peripheral blood
monocytes in humans or bone marrow cells in mice) in the presence of granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) [15]. In more recent years, an alternative
type of DCs called “IL-15 DCs” differentiated in the presence of GM-CSF and interleukin-15
(IL-15) has also emerged as an efficient and potentially more immunogenic vaccine for therapeutic
applications [16–18]. Instead, for maturation, a much wider variety of cytokine cocktails have been used
by different groups [10]. In particular, a cocktail mixture containing tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2), is currently considered the
gold standard for DC maturation and had been largely used in the context of anti-cancer therapeutic
vaccines [19,20]. This mix is able to efficiently induce expression of common DC surface maturation
markers, uniform DC maturation, as well as high levels of T cell proliferation and priming [19].
However, DCs matured with this mixture failed to produce significant levels of interleukin-12 (IL-12) a
crucial signal for T cell activation and Th1 differentiation [21]. On the other hand, our group previously
demonstrated that DC maturation in the presence of lipopolysaccharide (LPS) and interferon-γ (IFN-γ)
led to high levels of IL-12 production [22,23], an approach that was subsequently translated also into a
phase I clinical trial with promising results [12,13,24]. In addition to this, other groups also successfully
matured DCs in the presence of CD40 ligand and IFN-γ [25], or toll-like receptor ligands [26].
Based on this collective evidence, in this study, we characterize and compare the efficacy of DCs
differentiated with either IL-4 or IL-15 and a cocktail of differentiation and maturation stimuli in a
mouse model of metastatic ovarian cancer in an attempt to improve currently available DC vaccine
formulations (Figure 1). Our results demonstrate that DCs differentiated with GM-CSF and IL-15
and matured in the presence of anti-CD40, anti-PGE2, anti-PGE2 receptor (EP2), anti-IL-10 receptor
antibodies and CpG oligonucleotides (CpG) (in addition to the canonical LPS and IFNγ) exhibited
higher levels of anti-tumor response compared to canonical DC formulations. These results strongly
support further implementation of this DC formulation in future cancer vaccine clinical trials.
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Figure 1. Schematic representation of the DC preparation protocol for animal vaccination. DC cell 
precursors were first isolated from the bone marrow of tumor-bearing mice and subsequently 
incubated with the stimuli indicated in the table for 4 days (1. differentiation mix). Immature DCs 
were then pulsed with squaric acid-treated ID8 cell lysate by overnight incubation. Finally, DCs were 
then matured by incubation with the stimuli indicated in the table (3. maturation mix). In particular, 
the maturation process was achieved either in one single step with 24 h incubation, or in two 
subsequent steps with incubation with the indicated reagents for 3 h (step 1), followed by overnight 
incubation with the indicated reagents (step 2). (DC: dendritic cells) 
2. Results 
2.1. Differentiation with GM-CSF and IL-15 Yields a More Immunogenic DC Phenotype than Canonical 
DCs Differentiated with GM-CSF and IL-4 
In order to compare their immunogenic phenotype, we first differentiated DCs in vitro from the 
bone marrow of tumor bearing animals with GM-CSF and IL-4 (GM4-1 step DCs) or with GM-CSF 
and IL-15 (GM15-1 step DCs), pulsed with a squaric acid treated-ID8 tumor cell lysate (LSQ) and 
finally matured them with LPS plus IFNγ. After cell maturation, DC phenotypes were assessed by 
antibody staining against common surface markers such as: MHC-I, MHC-II, CD83, CD86, F4/80, and 
Toll-like receptors (TLRs) (Figure 2A, Figure S1) as well as for intracellular levels of key 
immunosuppressive (Figure 2B) and immunostimulatory (Figure 2C) cytokines by FACS analysis. 
Results showed that GM15-1 step DCs have significantly much higher MHC-II and CD86 expression, 
but lower MHC-I and TLR7 expression compared to GM4-1 step DCs (Figure 2A). In terms of 
cytokine release, although GM15-1 step DCs produced significantly lower TNFα and IFNγ, these 
DCs generated more IL-12/23p40 and less SOCS1 compared to GM4-1 step DCs. Other tested markers 
such as interleukin 10 (IL-10), TLR4, TLR8, transforming growth factor-β (TGFβ) and indoleamine 
2,3-dioxygenase (IDO) did not reveal any significant changes (Figure 2A–C). 
Given the advantageous increase in IL-12 as well as class-II MHC and CD86, and recent data 
suggesting the improved efficacy DCs differentiated with IL-15 [16,27–29], we chose the GM15-1 step 
backbone for further improvements, focusing in particular on enhancing IFNγ production. 
Figure 1. Schematic representation of the DC preparation protocol for animal vaccination. DC cell
precursors were first isolated from the bon marrow of tumor-bearing mice and subseq ently incubated
with the stimuli indicated in the t ble for 4 d ys (1. differentiation mix). Immature DCs were then
pulsed wit squaric acid-treated ID8 cell lysate by overnight incubation. Finally, DCs were then matured
by incubation with the stimuli indicated in the table (3. maturation mix). In particular, the maturation
process was achieved either in one single step with 24 h incubation, or in two subsequent steps with
incubation with the indicated reagents for 3 h (step 1), followed by overnight incubation with the
indicated reagents (step 2). (DC: dendritic cells)
2. Results
2.1. Differentiation with GM-CSF and IL-15 Yields a More Immunogenic DC Phenotype than Canonical DCs
Differentiated with GM-CSF and IL-4
In order to compare their immunogenic phenotype, we first differentiated DCs in vitro from the
bone marrow of tumor bearing animals with GM-CSF and IL-4 (GM4-1 step DCs) or with GM-CSF and
IL-15 (GM15-1 step DCs), pulsed with a squaric acid treated-ID8 tumor cell lysate (LSQ) and finally
matured them with LPS plus IFNγ. After cell maturation, DC phenotypes were assessed by antibody
staining against common surface markers such as: MHC-I, MHC-II, CD83, CD86, F4/80, and Toll-like
receptors (TLRs) (Figure 2A, Figure S1) as well as for intracell lar levels of key immunosuppressive
(Figur 2B) and immunostimulatory (Figure 2C) ytokines by FACS analysis. Results showed that
GM15-1 step DCs have significantly much higher MHC-II and CD86 expression, but lower MHC-I
and TLR7 expression compared to GM4-1 step DCs (Figure 2A). In terms of cytokine release,
although GM15-1 step DCs produced significantly lower TNFα and IFNγ, these DCs generated more
IL-12/23p40 and less SOCS1 compared to GM4-1 step DCs. Other tested markers such as interleukin
10 (IL-10), TLR4, TLR8, transforming growth factor-β (TGFβ) and indoleamine 2,3-dioxygenase (IDO)
did not reveal any significant changes (Figure 2A–C).
Given the advantageous increa e in IL-12 as well s class-II MHC and CD86, and recent data
suggesting the improved efficacy DCs differentiated with IL-15 [16,27–29], we chose the GM15-1 step
backbone for further improvements, focusing in particular on enhancing IFNγ production.
In particular, based on previous evidence showing the ability of CD40 ligand to induce DC
maturation and activation [30–32] and the ability of stimulated DCs to produce high levels of
IL-10 [33,34], we decided to include both anti-CD40 and IL-10 receptor (IL-10R) antibodies in an
attempt to improve the maturation process and achieve a more immunogenic DC phenotype.
To achieve this, after differentiation with GM-CSF and IL-15 and LSQ antigen pulsing we applied the
maturation stimuli in two steps, incubating DCs first with anti-CD40 plus anti-IL10R antibodies for
24 h, followed by the well-established maturation cocktail containing LPS and IFNγ with the addition
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of CpG (a potent TLR agonist [35]), for the subsequent 24 h (GM15-2 step DCs). After maturation we
assessed the phenotype of these DCs by FACS analysis (Figure 3A–E).Cancers 2019, 11, x 4 of 22 
 
 
Figure 2. Phenotypic comparison between mouse DCs differentiated ex vivo from bone marrow 
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or IL-15 (GM15-1 step) as indicated, pulsed with an ID8 tumor cell lysate treated with squaric acid 
and subsequently matured with LPS/IFNγ. Expression levels of indicated markers were then assessed 
by antibody staining followed by FACS analysis. The net mean fluorescence intensity (ΔMFI = Raw 
MFI-MFI of Isotype) for each marker is reported in the graph; data are representative of 3 independent 
experiments. Significant differences were assessed with unpaired Student’s t test and indicated with 
asterisks: * p < 0.05; ** p < 0.01. (DC: dendritic cells; GM-CSF: granulocyte-macrophage colony-
stimulating factor; IL-4: interleukin-4; IL-15: interleukin-15; IFN-γ: interferon-γ; LPS: 
lipopolysaccharide). 
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Figure 2. Phenotypic comparison between mouse DCs differentiated ex vivo fro bone marrow
precursors in the presence of GM-CSF and either IL-4 or IL-15. (A–C) Isolated mouse bone marrow
cells were differentiated in vitro for 4 days in the presence of GM-CSF and either IL-4 (GM4-1 step) or
IL-15 (GM15-1 st p) as indicated, pulsed with an ID8 tumor cell lysate tr ated with squaric acid and
subsequently matured with LPS/IFNγ. Expression levels of indicated markers were then assessed
by antibody staining followed by FACS analysis. The net mean fluorescence intensity (∆MFI = Raw
MFI-MFI of Isotype) for each marker is reported in the graph; data are representative of 3 independent
experiments. Sig ificant differences were assessed with unpaired Student’s t test and indicated with
asterisks: * p < 0.05; ** p < 0.01. (DC: dendritic cells; GM-CSF: granulocyte-macrophage colony-stimulating
factor; IL-4: interleukin-4; IL-15: interleukin-15; IFN-γ: interferon-γ; LPS: lipopolysaccharide).
Interestingly, introducing this new maturation scheme in DCs differentiated with GM-CSF and
IL-15 (GM15-2 step DCs) led to a further and significant increase in MHC-II, CD86 as well as TLR4,
and decrease in IDO expression, compare to IL-15 DCs matured in the presence of just LPS and IFNγ
(GM15-1 step DCs, Figure 3A,B). A significant increase in IL-12/23p40 and IFNγ production was seen
in GM15-2 step DCs compared to GM15-1 step DCs (Figure 3C).
In addition to this, we then further compared the same 2-step maturation protocol in DCs
differentiated in the presence of IL-4/GM-CSF (GM4-2 step DCs), or IL-15/GM- F. Our results
showed that the latter (GM15-2 step DCs) exhibited higher MHC-II, CD86, TLR4, IL-12/23p40, IL-12p35
and IFNγ, and lower IDO and suppressor of cytokine signaling 1 (SOCS1) relative to GM4-2 step DCs,
suggesting a potentially more immunogenic phenotype (Figure 3D,E).
Next, we proceeded to compare the efficiency of these different DC formulations in eliciting
anti-tumor T cell responses. To achieve this, we prepared DCs as above, we incubated them with
purified T cells from the spleen of ID8 tumor bearing mice for 24 h, and finally measured cytokines
levels in the supernatant by ELISA. Results showed that GM15-2 step DCs induced significantly
higher IFNγ production compared to all the other tested DC formulations and lower IL-4 generation
compared to IL-4 derived DCs, both trends indicative of a Th1-skewed T cell response (Figure 3F,G).
Similar results were also obtained from T cells purified from mesenteric and inguinal draining lymph
nodes or peritoneum (Figure S2).
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Figure 3. DCs matured with a two-step protocol in the presence of anti-CD40 and anti-IL10R 
antibodies for 24 h, followed by LPS/IFNγ/CpG stimuli present a more mature phenotype and 
stimulate a more Th1-skewed T cell response compared to canonical LPS/IFNγ maturation. (A–E) 
Immature antigen-pulsed DCs were obtained in the presence of either IL4 (GM4) or IL-15 (GM15) as 
Figure 3. DCs matured with a two-step protocol in the presence of anti-CD40 and anti-IL10R antibodies
for 24 h, followed by LPS/IFNγ/CpG stimuli present a more mature phenotype and stimulate a
more Th1-skewed T cell response compared to canonical LPS/IFNγ maturation. (A–E) Immature
antigen-pulsed DCs were obtained in the presence of either IL4 (GM4) or IL-15 (GM15) as reported
in Figure 2. Cells were then pulsed with an ID8 tumor cell lysate treated with squaric acid and
subsequently matured in the presence of either LPS/IFNγ for 24 h (GM15-1 step, GM4-1 step) or with
a cocktail mix containing anti-CD40 and anti-IL-10R for 24 h, followed by a second mix containing
LPS, IFNγ and CpG for the subsequent 24hr (GM4-2 step, GM15-2 step). Expression levels of indicated
markers were then assessed by antibody staining followed by FACS analysis. The net mean fluorescence
intensity (∆MFI = Raw MFI-MFI of Isotype) for each marker is reported in the graph. (F,G) IFNγ
and IL-4 production measured by ELISA after 24 h co-culturing of splenic T-lymphocytes isolated
from tumor bearing animals with the indicated DC formulations. Data are representative of at least
3 independent experiments. Significant differences were assessed with unpaired Student’s t test
and indicated with asterisks: * p < 0.05; ** p < 0.01; *** p < 0.005. (CpG: CpG oligonucleotides; DC:
dendritic cells; GM-CSF: granulocyte-macrophage colony-stimulating factor; IL-4: interleukin-4; IL-10R:
interleukin-10 receptor; IL-15: interleukin-15; IFN-γ: interferon-γ; LPS: lipopolysaccharide).
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Following in vitro studies, we proceeded to compare the efficacy of GM15-2 step DCs with the
conventional GM4-1 step DCs in vivo in the ID8 ovarian cancer mouse model. To achieve this, we first
inoculated ID8 cells intraperitoneally (i.p.) in C57BL/6 mice on day 0 and subsequently injected
GM4-1 step or GM15-2 step DCs or placebo (phosphate-buffered saline (PBS)) i.p. on day 7, day 14
and day 21 post tumor inoculation, then following animal survival over time (Figure 4A). Interestingly,
we observed that mice vaccinated with GM15-2 step DCs displayed a significant distinct survival
advantage over mice vaccinated with conventional DCs (GM4-1 step DCs; p < 0.05) or placebo (p < 0.05)
(Figure 4B). In particular, the median survival in the placebo group was ~40 days, while mice receiving
GM4-1 step DCs had a median survival of about ~65 days, compared to ~80 days for the GM15-2 step
DC-treated group. These results confirmed therefore the superiority of GM15-2 step DCs also in the
in vivo context compared to canonical IL-4 differentiated DCs (GM4-1 step DCs).
Cancers 2019, 11, x 6 of 22 
 
reported in Figure 2. Cells were then pulsed with an ID8 tumor cell lysate treated with squaric acid 
and subsequently matured in the presence of either LPS/IFNγ for 24 h (GM15-1 step, GM4-1 step) or 
with a cocktail mix containing anti-CD40 and anti-IL-10R for 24 h, followed by a second mix 
containing LPS, IFNγ and CpG for the subsequent 24hr (GM4-2 step, GM15-2 step). Expression levels 
of indicated markers were then assessed by antibody staining followed by FACS analysis. The net 
mean fluorescence intensity (ΔMFI = Raw MFI-MFI of Isotype) for each marker is reported in the 
graph. (F,G) IFNγ and IL-4 production measured by ELISA after 24 h co-culturing of splenic T-
lymphocytes isolated from tumor bearing animals with the indicated DC formulations. Data are 
representative of at least 3 independent experiments. Significant differences were assessed with 
unpaired Student’s t test and indicated with asterisks: * p < 0.05; ** p < 0.01; *** p < 0.005. (CpG: CpG 
oligonucleotides; DC: dendritic cells; GM-CSF: granulocyte-macrophage colony-stimulating factor; 
IL-4: interleukin-4; IL-10R: interleukin-10 receptor; IL-15: interleukin-15; IFN-γ: interferon-γ; LPS: 
lipopolysaccharide). 
In addition to this, we then further compared the same 2-step maturation protocol in DCs 
differentiated in the presence of IL-4/GM-CSF (GM4-2 step DCs), or IL-15/GM-CSF. Our results 
showed that the latter (GM15-2 step DCs) exhibited higher MHC-II, CD86, TLR4, IL-12/23p40, IL-
12p35 and IFNγ, and lower IDO and suppressor of cytokine signaling 1 (SOCS1) relative to GM4-2 
step DCs, suggesting a potentially more immunogenic phenotype (Figure 3D,E). 
Next, we proceeded to compare the efficiency of these different DC formulations in eliciting anti-
tumor T cell responses. To achieve this, we prepared DCs as above, we incubated them with purified 
T cells from the spleen of ID8 tumor bearing mice for 24 h, and finally measured cytokines levels in 
the supernatant by ELISA. Results showed that GM15-2 step DCs induced significantly higher IFNγ 
production compared to all the other tested DC formulations and lower IL-4 generation compared to 
IL-4 derived DCs, both trends indicative of a Th1-skewed T cell response (Figure 3F,G). Similar results 
were also obtained from T cells purifie  from mesente ic and inguinal draining lymph nodes or 
peritoneum (Figure S2). 
Following in vitro studies, we proceeded to compare the efficacy of GM15-2 step DCs with the 
conventional GM4-1 step DCs in vivo in the ID8 ovarian cancer mouse model. To achieve this, we 
first inoculated ID8 cells intraperitoneally (i.p.) in C57BL/6 mice on day 0 and subsequently injected 
GM4-1 step or GM15-2 step DCs or placebo (phosphate-buffered saline (PBS)) i.p. on day 7, day 14 
and day 21 post tumor inoculation, then following animal survival over time (Figure 4A). 
Interestingly, we observed that mice vaccinated with GM15-2 step DCs displayed a significant 
distinct survival advantage over mice vaccinated with conventional DCs (GM4-1 step DCs; p < 0.05) 
or placebo (p < 0.05) (Figure 4B). In particular, the median survival in the placebo group was ~40 days, 
while mice receiving GM4-1 step DCs had a median survival of about ~65 days, compared to ~80 days 
for the GM15-2 step DC-treated group. These results confirmed therefore the superiority of GM15-2 
step DCs also in the in vivo context compared to canonical IL-4 differentiated DCs (GM4-1 step DCs). 
 
Cancers 2019, 11, x 7 of 22 
 
 
Figure 4. DCs matured with a two-step protocol in the presence of anti-CD40 and anti-IL10R 
antibodies for 24hr, followed by LPS/IFNγ/CpG stimuli prolong animal survival in a vaccination 
mouse model of ovarian cancer. (A) Vaccination scheme: mice were inoculated i.p. with ID8 cells at 
day 0, followed by i.p. vaccination with the indicated DC formulations (pulsed with an ID8 tumor cell 
lysate treated with squaric acid (LSQ) or kept unpulsed (Unp)) at day 7, 14 and 21 (n ≥ 5 for each 
group). (B,C) Body weight and animal survival were evaluated and plotted in Kaplan–Meier 
cumulative survival plots. Student’s t test results (comparing GM15-2 step DCs (LSQ) to both GM4-1 
step DCs (LSQ) and placebo) is indicated with an asterisk: * p < 0.05. (CpG: CpG oligonucleotides; DC: 
dendritic cells; IFN-γ: interferon-γ; LPS: lipopolysaccharide). 
2.2. Improving the Efficacy of GM15-2 Step DCs through Inhibiting the Prostaglandin Pathway 
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differentiation [36], function [37,38] and IL-12 production [36], we next focused on further improving 
our DC preparation protocol to achieve an even more immunogenic DC vaccine by introducing an 
antibody against PGE2 and one against its putative receptor EP2 throughout the DC culture. The 
phenotype of the resultant DCs (DC5) was then assessed by antibody staining followed by FACS 
analysis (Figure 5A,B). Results showed significantly increased levels of MHC-I, MHC-II, IL-12p35, 
IL12/23p40 and IL-1α in DC5, compared to the previously developed GM15-2 step DCs, while CD86, 
TNFα and cytokine-inducible nitric oxide synthase (iNOS) levels were essentially comparable (Figure 
5A,B). 
Figure 4. DCs matured with a two-step protocol in the presence of anti-CD40 and anti-IL10R antibodies
for 24 h, followed by LPS/IFNγ/CpG stimuli prolong animal survival in a vaccination mouse model
of ovarian cancer. (A) Vaccination scheme: mice were inoculated i.p. with ID8 cells at day 0, followed
by i.p. vaccination with the indicated DC formulations (pulsed with an ID8 tumor cell lysate treated
with squaric acid (LSQ) or k pt unpulsed (Unp)) at day 7, 14 nd 21 ( ≥ 5 for each group). (B,C) Body
weight and animal survival were evaluated and pl tted Kaplan–Meier cumulative survival plots.
Student’s t test results (comparing GM15-2 step DCs (LSQ) to both GM4-1 step DCs (LSQ) and placebo)
is indicated with an asterisk: * p < 0.05. (CpG: CpG oligonucleotides; DC: dendritic cells; IFN-γ:
interferon-γ; LPS: lipopolysaccharide).
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2.2. Improving the Efficacy of GM15-2 Step DCs through Inhibiting the Prostaglandin Pathway
Based on previous evidence suggesting an immunosuppressive activity of PGE2 on DC
differentiation [36], function [37,38] and IL-12 production [36], we next focused on further improving
our DC preparation protocol to achieve an even more immunogenic DC vaccine by introducing
an antibody against PGE2 and one against its putative receptor EP2 throughout the DC culture.
The phenotype of the resultant DCs (DC5) was then assessed by antibody staining followed by
FACS analysis (Figure 5A,B). Results showed significantly increased levels of MHC-I, MHC-II,
IL-12p35, IL12/23p40 and IL-1α in DC5, compared to the previously developed GM15-2 step DCs,
while CD86, TNFα and cytokine-inducible nitric oxide synthase (iNOS) levels were essentially
comparable (Figure 5A,B).
Cancers 2019, 11, x 8 of 22 
 
 
Figure 5. Blocking the prostaglandin E2 pathway during DC differentiation and maturation improves 
DC phenotype and in vitro immunogenicity. (A,B) Isolated mouse bone marrow cells were 
differentiated in the presence of GM-CSF and IL-15 (GM15-2 step DCs) for 4 days or first with GM-
CSF and IL-5 for 24h then supplemented with anti-PGE2, anti-EP2 Ab (DC5); cells were then pulsed 
and matured as reported in Figure 3 for GM15-2 step DCs with the addition of anti-PGE2, anti-EP2 
Ab for DC5 throughout the cell culturing period. Cell phenotype was then analyzed by FACS staining 
and the net mean fluorescence intensity (ΔMFI = Raw MFI-MFI of Isotype) for each marker was 
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co-culturing of T-lymphocytes isolated from the ascites (Asc), lymph node (LN), or spleen (Sp) of 
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treated with squaric acid. Data are representative of at least 3 independent experiments. Significant 
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We then tested the in vitro induced T-cell responses by co-culturing GM15-2 step DCs or DC5 
(prepared from bone marrow cells of tumor bearing animals) with T cells derived from ascites, spleen 
or draining lymph nodes of tumor bearing animals for 24 h and subsequently measuring levels of 
Figure 5. Blocking the prostaglandin E2 pathway during DC differentiation and maturation
improves DC phenotype and in vitro immunogenicity. (A,B) Isolated mouse bone marrow cells were
differentiated in the presence of GM-CSF and IL-15 (GM15-2 step DCs) for 4 days or fir t with GM-CSF
and IL-5 for 24 h then supplemented with anti-PGE2, anti-EP2 Ab (DC5); cells were then pulsed and
matured as reported in Figure 3 for GM15-2 step DCs with the addition of anti-PGE2, anti-EP2 Ab
for DC5 throughout the cell culturing per od. Cell phenotype was then analyzed by FACS staining
and the net mean fluorescence intensity (∆MFI = Raw MFI-MFI of Isotype) for each marker was
reported in the graph. (C–F) Levels of indicated cytokines measured by ELISA, produced after 24 h
co-culturing of T-lymphocytes isolated from the asci es (As ), lymph node (LN), or spleen (Sp) of
tumor bearing animals with the indicated DC formulations pulsed with an ID8 tumor cell lysate
treated with squaric acid. Data are representative of at least 3 independent experiments. Significant
differences were asse sed w th unpaired Student’s t test and indicated with asterisks: * p < 0.05;
** p < 0.01; *** p < 0.005. (CpG: CpG oligonucleotides; DC: dendritic cells; EP2: PGE2 receptor; GM-CSF:
granulocyte-macrophage colony-stimulating factor; IL-15: interleukin-15; PGE2: prostaglandin E2).
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We then tested the in vitro induced T-cell responses by co-culturing GM15-2 step DCs or DC5
(prepared from bone marrow cells of tumor bearing animals) with T cells derived from ascites, spleen
or draining lymph nodes of tumor bearing animals for 24 h and subsequently measuring levels of
IFNγ, IL-4, TGFβ and IL-10 in the culture supernatant by ELISA. Results showed that while levels of
IFNγ were essentially comparable between the two different DC preparations in use (when comparing
between same T cells types, Figure 5C; except in the case of splenic T cells), IL-4 and IL-10 levels
were significantly lower in co-cultures of ascites T cells with LSQ antigen-pulsed DC5 DCs compared
to the respective GM15-2 step DC counterpart (Figure 5D,E). DC5 DCs also induced significantly
less IL-4 when co-cultured with splenic T cells compared to GM15-2 step DCs (Figure 5D). Finally,
LSQ antigen-pulsed DC5 elicited significantly lower amounts of TGFβ in co-cultures of lymph node
and splenic T cells compared to GM15-2 step DCs (Figure 5F). Thus, the in vitro results here presented,
taken collectively, suggest that DC5 display a more advantageous DC phenotype than the previously
characterized GM15-2 step DCs, they induce a more favorable cytokine profile in co-cultured T cells
and they can be therefore considered more immunogenic.
We next proceeded to test the therapeutic efficacy of DC5 in vivo. To achieve this, we injected
i.p. 8–10 week old female mice with ID8 cells on day 0. We then injected i.p. placebo (PBS), GM15-2
step or DC5 unpulsed or LSQ antigen-pulsed on days 7, 14 and 21 post tumor inoculation and
followed animal survival over time. We observed that therapeutic vaccination with antigen-pulsed
DC5 could significantly (p < 0.01) delay tumor progression and impart a much higher survival
advantage compared to vaccination with LSQ antigen-pulsed GM15-2 step DCs or classical GM4-1
step DCs (Figure 6A–C). While the median survival for placebo controls was 36 days post inoculation,
this increased to 49 days with therapeutic vaccination with LSQ antigen-pulsed GM4 DCs, to 65 days
with GM15-2 step DCs and to 110 days with DC5 DCs.
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To test the tumor specificity of the T cell response as well as the memory response elicit d by
therapeutic vaccination with DC5 DCs, we then performed adoptive T cell transfer experiments.
The donors were ID8 tumor bearing female C57BL/6 mice, either kept untreated or therapeutically
treated with DC5 (i.p.) on days 7, 15 and 21 post tumor inoculation. Lymph node (LN) cells were
then collected from inguinal LN on day 28 post tumor inoculation and T cells isolated by negative
selection. T cells were then injected in the tail vein of recipient mice 3 days before tumor challenge with
i.p. injection of ID8 cells. Animal survival measurements presented in Figure 6D showed that T cells
from lymph nodes of animals therapeutically vaccinated with DC5, when transferred to naïve animals,
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conferred considerable prophylactic protection and delayed tumor establishment and progression
compared to that conferred by T cells from placebo controls.
2.3. Characterization of the T Cell Response Induced by Vaccination with DC5 DCs
Based on the fact that vaccination with the DC5 formulation conferred the highest survival
advantage in the present study, we decided to further characterize its induced T cell response and
compare it with the one elicited by classical GM4-1 step DC vaccination which is the current golden
standard for DC vaccines in clinical settings. To achieve this, we first established metastatic tumors
by injecting i.p. ID8 cells (day 0) in 8–10 week old female C57BL6 mice, followed by i.p. vaccination
with DCs (or placebo) on days 7, 14 and 21 post tumor inoculation. Then, at 42 days post tumor
inoculation, we isolated cells from the peritoneal cavity and performed a flow cytometric analysis for
different markers of cell cytotoxicity. Interestingly, we observed that in the CD8+ cell compartment
both the expression (in terms of ∆MFI) and the percentage of granzyme B+ T cells were significantly
higher in DC5 vaccinated animals compared to animals vaccinated with GM4-1 step DCs or placebo
(Figure 7A). A similar analysis was also repeated for CD8+ T cells isolated by negative selection from
draining lymph nodes and spleen, showing that DC5 vaccination induced significantly higher levels of
granzyme B+ T cells also in these animal loci compared to the other two conditions (authors personal
observation). Additionally, in the peritoneum cell compartment we also observed that, although the
percentage of CD4+ T cells expressing IL-10 was comparable between animals vaccinated with GM4-1
step DCs and DC5, the amount expressed (in terms of ∆MFI) in the latter case was significantly lower
(Figure 7B). Interestingly, CD45+ peritoneal cells form DC5 vaccinated animals also presented higher
expression (in terms of ∆MFI) and percentage of perforin+ cells compared to control counterparts
(Figure 7C).
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i r 7. Vaccination with DC5 DCs increases cell activation and cytotoxicit of the T cell compartment
at tumor site. (A–C) ID8 fast cells were inject d i.p. in 8–10 weeks old female C57BL6 mice; mice were
then vaccinated i.p. with the in icated DC formulation (or placebo) on day 7, day 14 an day 21 post
tumor inoculation. 42 days post tumor inoculation cells isolated from the ascite fluid (in the case of
placebo control animals) or obtained by peritoneal lavage (in vaccinated animals that presented no
ascites) were stained with the indicated markers and analyzed by flow cytometric analysis. (D) RNA
levels of indicated markers were analyzed by qPCR in CD45+ cells isolated as reported above. Data are
representative of at least 3 independent experiments. Significant differences were assessed with
unpaired Student’s t test and indicated with asterisks: * p < 0.05; ** p < 0.01. (DC: dendritic cells; qPCR:
quantitative polymerase chain reaction).
Given that we used an intra-peritoneal model of ovarian cancer, we also performed a qPCR
analysis of the whole CD45+ population from peritoneum of vaccinated animals to get a better
understanding of the tumor microenvironment. Analyses showed that DC5 vaccinated animals were
characterized by significantly lower GATA3, SOCS3, IL-10, IL-4, TGF-β mRNA and higher tbet and
IFNγ levels compared to GM4-1 step vaccinated animals; all indicative of a Th1-skewed T cell response
(Figure 7D).
Finally, we cultured T cells isolated from vaccinated animals with autologous DCs pulsed with
LSQ (or unpulsed DCs in case of placebo), in the presence of IL-12 for 24 h and analyzed cytokine levels
by qPCR. T cells isolated from the peritoneum of animals vaccinated with DC5 were superior in terms of
perforin, granzyme B, IFNγ and IL-9 mRNA levels compared to both the respective placebo and classical
GM4-1 step DC counterparts (Figure 8A). In the instance of T cells isolated from draining lymph
nodes, DC5 vaccination induced higher granzyme B and IL-9 mRNA levels compared to GM4-1 step
vaccination; while perforin and IFNγ levels were comparable between the two conditions (Figure 8B).
On the other hand, T cells isolated from the spleen of DC5 vaccinated animals showed lower granzyme
B, IFN-γ, TGF-β and IL-10 mRNA levels, compared to GM4-1 step vaccinated animals (Figure 8C).
These results, and in particular the pronounced perforin 1, granzyme B, IFNγ, and IL-9 mRNA
expression by peritoneal T cells along with low levels of IL-10 and TFGβ mRNA are indicative of a
high anti-tumor effector potential induced by vaccination with DC5 DCs.
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3. Discussion
It is k own that GM-CSF a d IL-15 can differe tiate bo mouse bone marrow cells and human
CD14+ monocytes into DCs (IL-15 DCs) [18,39]. Recently, it has been shown that these DCs can
efficiently initiate both Th1 and Th17 responses [17] and mount an anti-cancer immune response
against melanoma [40]. Thus, several groups subs quently brought these cells into cli ical trials for
cancer therapeutics with moderate succe s (NCT01456104, NCT01189383) [16,41]. On the other hand,
DCs differentiated in the presence of GM-CSF and IL-4 (IL-4 DCs) represent the gold standard for DC
therapeutic vaccination and have been tested in clinical trials for more than 20 years [42]. Despite the
many efforts and advancements over the years, data meta-analysis demonstrated that this therapeutic
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intervention could only increase overall survival by ~20%, to date [43]. Given the crucial role played
by DCs in orchestrating both innate and adaptive immune responses it is generally believed that new
improvements could further improve clinical outcomes and harness the true therapeutic potential of
DCs. In search for a more powerful vaccine, we compared the efficacies of IL-15 DCs and IL-4 DCs in
the context of a metastatic murine ovarian cancer model. Differentiation of bone marrow cells to DCs
in the presence of GM-CSF and IL-15, followed by the same maturation stimuli as conventional IL-4
DCs, resulted in higher CD86, MHC-II expression and higher IL-12p40 generation compared to the
latter, indicating that this DC preparation expresses more co-stimulatory molecules and might be better
equipped to activate T cell responses skewed towards a Th1 type. However, these DCs generated
lower amounts of IFNγ and TNFα and similar IL-10 production to that produced by conventional
GM4-1 step DCs.
The CD40/CD40L axis is an important licensing signal that enables DCs to subsequently
prime naïve cytotoxic T lymphocytes [44] and CD40 ligands have also been previously shown to
be potent inducers of DC maturation and activation [30–32]. On the other hand, it is well known
that after stimulation, dendritic cells produce high levels of IL-10 [33,34], one of the most potent
immunosuppressive cytokines, partially hampering DC full maturation. Previous evidence suggests
that the addition of an anti-IL10 antibody blocks these IL-10 autocrine immunosuppressive effects,
leading to increase DC maturation and T cell activation [33]. Hence, based on this collective evidence
we then further introduced a blocking antibody against the IL10 receptor and a CD40 ligand during
the first step of the maturation process in an attempt to further improve DC efficacy. In the last 24 h
of the maturation process we further introduced LPS, IFNγ and CpG, three canonical maturation
stimuli, to ensure full maturation status. Phenotypic analysis of the so-obtained DCs showed a drastic
reduction of IDO expression, and an increase in IL-12/23p40, TLR4 and MHC-II expression, compared
to classical LPS/IFNγ maturation. Interestingly, previous observations demonstrated the role of CD40L
in upregulating TLR4 expression [45], suggesting that, in our case, pre-incubation of DCs with CD40L
may indeed induce higher TLR4 expression leading to a higher responsiveness to subsequent LPS
stimulation (a known putative TLR4 ligand), ultimately promoting a higher DC maturation status.
Either way, as a consequence of their higher immunogenic phenotype, GM-15-2 step DCs elicited a
T-cell response strongly skewed toward Th1 when co-cultured with splenic, lymph node or peritoneal
T cells isolated from tumor bearing animals, when compared to those elicited by canonical GM4-1 step,
GM4-2 step or GM15-1 step control counterparts. A corresponding significant improvement on overall
survival was also observed in a mouse model of ovarian cancer upon therapeutic vaccination with
GM15-2 step DCs.
Previous observations demonstrated that a strong interplay exists between malignant cells and
host cells present in the tumor proximity (e.g., tumor-associated macrophages and fibroblasts, T cells,
etc.) to create a tumor-promoting and immunosuppressive tumor microenvironment (TME) [46,47].
One of the major players in this context is prostaglandin E2 (PGE2), a lipid metabolite produced by
cyclooxygenase enzymes (COX1-2) whose activity has been linked to tumor progression [48] and
inversely correlated with CD8+ T cell tumor infiltration and patient survival [49]. Several studies
demonstrated that, in addition to inhibiting T cell interleukin-2 (IL-2) production [50], proliferation [50]
and tumor infiltration [49], PGE2 has also a major impact during the DC early stage development,
inducing a shift towards an immunosuppressive activity [37,38], impairing DC differentiation, IL-12
production [36], DC function [37,38], promoting the development of tolerogenic DCs [38] and hence
overall contributing to DC dysfunction in cancer [51]. Based on this evidence, we therefore decided to
introduce PGE2 and PGE2 receptor-blocking antibodies during both DC differentiation and maturation
process, in an attempt to counteract these actions [52]. Indeed, our results demonstrated that inhibiting
PGE2 signaling improved DC phenotype and yielded a marginal survival advantage in vivo. In fact,
the so-obtained DCs (designated as “DC5”) not only expressed higher levels of MHC-I and MHC-II,
IL-12 and IL-1α compared to GM15-2 step DCs, but also elicited an in vitro strong Th1 response marked
by high IFNγ and low IL-4, TGFβ and IL-10 from T cells isolated from different compartments of tumor
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bearing animals. While generally comparable to the GM15-2step induced ones, these responses were
even improved in certain instances according to the different tested T cell compartments. Furthermore,
when tested in vivo in the ID8 ovarian cancer mouse model, DC5 proved to be a much stronger
therapeutic vaccine compared to GM15-2 step DCs, conferring appreciable survival advantage as well
as a tumor specific memory response, as indicated by adoptive transfer experiments. T cells isolated
from animals therapeutically vaccinated with DC5 DCs in fact conferred a considerable survival
advantage and delayed tumor progression when transferred to naïve animals, compared to T cell
transfer from placebo controls, demonstrating the tumor specificity of the DC5-induced response.
Furthermore, characterization of the T cell compartment from vaccinated animals showed that DC5
vaccination is able to induce a more immunogenic and cytotoxic T cell profile. In particular, T cells in
the tumor proximity (peritoneum) presented higher perforin, granzyme B, lower IL-10 and a more
beneficial mRNA profile, compared to classical GM4-1 step vaccination. These data, taken collectively
strongly suggest that the protocol here developed for differentiation and maturation of DC5 DCs
from their bone marrow precursors constitute a valid and more beneficial alternative to standard DCs
obtained with “canonical” IL-4, LPS and IFNγ stimuli. Furthermore, the work here presented was
carried out with immune cells obtained from tumor-bearing mice. This aspect is of crucial importance
considering previous studies reporting several important functional and numeric deficiencies of DC
induced by tumors [53–56], further strengthening the evidence here presented in a more physiological
and clinically relevant context.
On the other hand, despite the fact that DC5 vaccination appreciably increased the median
survival against a huge metastatic tumor load, these DCs still failed to cure mice in the present
study, partly due to the aggressiveness of this tumor model and partly due to the complicated tumor
microenvironment which is driving the field towards combinatorial therapy. Recently, it has been
proposed that the therapeutic effects of DC vaccines could be potentially further boosted with their
use in combination with checkpoint blockade inhibitors such as cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and Programmed cell death protein 1 (PD-1) blocking antibodies [10]. In fact, in this
way, while on one side the DC vaccine would stimulate a tumor-specific T cell response, on the other,
immune checkpoint inhibitors would further sustain the clonal expansion and cytotoxicity of these DC
vaccine-induced T cells. Hence, we envisage that future work should test and address this tantalizing
hypothesis with improved DC formulations such as DC5 both in the mouse model and in the clinic to
potentially improve therapeutic outcomes of DC vaccines, especially in the case of more advanced
stage tumors.
4. Materials and Methods
4.1. Reagents
Recombinant murine GM-CSF, IL-4, IL-15 and IFNγ were purchased from Peprotech, Rocky Hill,
NJ, USA. Anti-IL-10R (CD210) antibody was purchased from Biolegend, San Diego, CA, USA.
Anti-CD40 monoclonal antibody (FGK-45) was procured from Enzo Lifesciences, Farmingdale, NY,
USA. All fluorescent antibodies and their isotype controls were purchased from Biolegend, USA
unless stated otherwise. Anti-IL-12p35-eFluor660, anti-IL-10-PE, anti-TNFα-PE/Cy7, anti-IFNγ-APC,
anti-IL-12/23p40-PerCP/Cy5.5, anti-TLR9 (CD289)-biotin, anti-Thymic stromal lymphopoietin (TSLP)
functional grade antibodies and Human/Murine TGFβ ELISA kit were purchased from eBiosciences,
Waltham, MA, USA. Anti-TGFβ1-LAP antibody was purchased from Thermo Scientific, Waltham, MA,
USA. Anti-SOCS1 and anti-SOCS3 antibodies were purchased from Millipore (Upstate), Burlington,
MA, USA. Anti-Prostaglandin E2 (PGE2) and anti-prostaglandin receptor 2 (EP2) antibodies were
purchased from Abcam, Cambridge, MA, USA. OptEIA ELISA sets for mouse IFNγ, IL-10 and IL-4
were from BD Biosciences, San Jose, CA, USA. ODN 1585 CpG was purchased from InvivoGen,
San Diego, CA, USA. Cell culture medium and Dulbecco’s Phosphate-Buffered Saline (DPBS) were
from CellGro Media Tech, Waltham, MA, USA. Fetal Calf Serum was purchased from Gibco,
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Life Technologies, Waltham, MA, USA. CD45+ cell purification system was purchased from Miltenyi
Biotech, Bergisch Gladbach, Germany. Unless mentioned otherwise, all other reagents were from
Sigma-Aldrich, Darmstadt, Germany. All kits for qPCR and kit for untouched T cells were purchased
from Invitrogen, Waltham, MA, USA. Streptavidin-PE, anti-TLR4-APC, anti-MHC-II (IA/IE-AF647),
CD86-AF488, CD83-PE, F4/80-BV421, goat anti-rat IgG-AF647 and goat anti-rat IgG-AF488 were
purchased from Biolegend.
4.2. Cell Lines and Animals
ID8 represents a cell line derived from spontaneous malignant transformation of C57BL/6
mouse cells in vitro [57] and was a generous gift from Dr. Paul F. Terranova, University of Kansas,
USA. Tumor cells were cultured in complete DMEM (Cellgro, New York, NY, USA) containing
10% heat-inactivated fetal bovine serum (FBS, Life Technologies) and antibiotics (Penstrep (Gibco,
Gaithersburg, MD, USA) at 10 U/mL culture medium and normocin, (Invitrogen, Waltham,
MA, USA) at 0.1 mg/mL culture medium). Cells were regularly tested for mycoplasma. Specific
pathogen-free grade 6–8 week-old female C57BL/6, OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J) and OT-II
(B6.CgTg(TcraTcrb)425Cbn/J) mice were purchased from the Jackson Laboratories, Sacramento, CA,
USA. Animals were maintained according to the institutional guidelines. The research obtained ethical
approval under the protocol # 803648 provided by the Institutional Animal Care & Use Committee of
the University of Pennsylvania (IACUC).
4.3. Preparation of Tumor Antigen
Squaric acid-treated tumor lysates for antigen pulsing were prepared as previously reported [14].
Briefly, ID8 cells were resuspended at a concentration of 108 cells/mL in 0.06% squaric acid for 1 h at
37 ◦C and subsequently lysed by 6 cycles of freeze and thaw, followed by sonication (5 watt output for
15 s, 3 repeats on ice with 30 s intervals).
4.4. Generation of Bone Marrow-Derived Mouse DCs
DCs were generated from murine bone marrow cells, as described by Garrigan K. et al. [58]
with minor modifications. Briefly, bone marrow was flushed from the long bones of ID8 tumor
bearing mice. A single cell suspension was cultured in RPMI 1640 (CellGro, New York, NY, USA)
supplemented with 10% heat-inactivated FBS (Life Technologies, USA), 2 mM L-glutamine (Gibco,
USA), 100 U/mL penicillin (Gibco, USA), 100 µg/mL streptomycin (Gibco, USA), 10 mM HEPES pH
7.4 (Gibco, USA), 0.5 mM sodium pyruvate (Cellgro, USA), 0.5% MEM non-essential amino acids
(Cellgro, USA), 0.1 mg/mL Normocin (InVivogen, San Diego, CA, USA). Cells were then differentiated
according to (Figure 1) and as follows: For GM4 DCs -1 step or -2 step: with 20 ng/mL recombinant
murine GM-CSF and 10 ng/mL IL-4 for 4 days (on day 2, the medium was replaced with fresh
medium containing same cytokines); for GM15 1-step/2-step and DC5s: with 20 ng/mL GM-CSF
and 10 ng/mL IL-15 for 4 days (on day 2, the medium was replaced with fresh medium containing
same cytokines). For DC5 DCs: on day 1 with 20 ng/mL GM-CSF and 10 ng/mL IL-15; on day 2,
the medium was replaced with fresh medium containing: GM-CSF (20 ng/mL), IL-15 (10 ng/mL)
and both anti-PGE2 (0.1 µg/mL) and anti-EP2 Ab (0.2 µg/mL). On day 4, DCs were kept unpulsed
or pulsed with squaric acid treated tumor lysate (LSQ) using ~1 tumor cell equivalent per DC and
incubated for 12–16 h. After pulsing, DCs were matured as follows: for GM4-1 step and GM15-1 step:
on day 5 the medium was removed and fresh medium containing 100 ng/mL LPS and 100 ng/mL
IFNγ was added and incubated for 24 h at 37 ◦C and 5% CO2. For GM4-2 step and GM15-2 step: on day
4 fresh medium containing anti-CD40 Ab FGK45 (0.2 µg/mL) + anti-IL-10R blocking Ab (0.5 µg/mL)
was added; on day 5, the medium was removed and fresh medium containing LPS (20 ng/mL), IFNγ
(100 ng/mL) and CpG-ODN 1585 (10 µg/mL) was added and kept for 24 h. For DC5 DCs: on day 4,
fresh medium containing anti CD40 Ab FGK45 (0.2 µg/mL) + anti-IL-10R blocking Ab (0.5 µg/mL) +
anti-EP2 Ab (0.1 µg/mL) + anti-PGE2 (0.1 µg/mL) was added. After 3h, the medium was removed
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and fresh medium containing anti-PGE2 (0.1 µg/mL), anti-EP2 Ab (0.2 µg/mL), LPS (20 ng/mL),
IFNγ (100 ng/mL) and CpG-ODN 1585 (10 µg/mL) was added and incubated overnight. Cells were
then harvested, stained with indicated antibodies followed by FACS analysis (Canto-II, BD bioscience,
San Jose, CA, USA) or used for animal vaccination.
4.5. DC Vaccination
1 × 106 DCs (resuspended in 500 µL DPBS) were injected i.p. on day 7, 14 and 21 following
intraperitoneal inoculation of 1 × 106 ID8 cells (in 500 µL DPBS) at day 0. Animals were monitored
regularly for tumor growth by measuring the body weight. Mice attaining 30 g body weight were
sacrificed (~40% increase in body weight over age/sex-matched normal mice).
4.6. Adoptive T Cell Transfer Experiments
ID8 tumor-bearing female C57BL/6 mice were vaccinated as reported above. Lymph node (LN)
cells were then collected from inguinal LN on day 28 post tumor inoculation and T cells isolated by
negative selection with the dynabeads mouse T cell kit (Thermofisher, Waltham, MA, USA), following
manufacturer instructions. 1 × 106 T cells were then injected in the tail vein of each recipient mice
3 days before tumor challenge with i.p. injection of ID8 cells (1× 106/animal). Animals were monitored
regularly for tumor growth. Mice attaining 30 g body weight were sacrificed (~40% increase in body
weight over age/sex-matched normal mice).
4.7. DC and T Cell Co-Culture
T cells from spleen or draining lymph nodes (mesenteric and inguinal) or ascites or peritoneal
exudate of normal and tumor bearing (ID8) animals (receiving 3 consecutive injections of placebo (PBS)
or DC vaccine on day 7, 14 and 21 post tumor inoculation) were purified using negative selection kit
(Invitrogen, USA). 1× 105 T cells were plated with 1× 104 DCs and cultured for 96h in a culture volume
of 200 µL. When indicated, the culture was treated with 5ng/mL recombinant mouse IL-12 (Peprotech,
USA). Cells were incubated with Brefeldin A (final concentration 2 µg/mL) for 8 h and then harvested.
Cells were then stained with indicated antibodies followed by FACS analysis (Canto-II, BD Biosciences)
or analyzed by RTqPCR. Cell-free culture supernatants were also taken to measure levels of indicated
cytokines by ELISA (OptEIA, BD Biosciences, USA) according to manufacturer procedures.
4.8. Reverse Transcription-Quantitative Polymerase Chain Reaction (RTqPCR)
RTqPCR was carried out using oligo-dT primer and Superscript-III reverse transcriptase (Thermo
Fisher, USA). Real time PCR was performed with standard primer-probe sets obtained from Thermo
Fisher, USA, following manufacturer instructions.
4.9. Statistical Analysis
SAS software (Version 9.3, SAS, Cary, NC, USA) and StatXact Procs 9 (Cytel, Cambridge, MA,
USA) for SAS were used for statistical analysis. In particular, a two-tailed Student’s t-test was used to
compare means of continuous measurements between two groups. The analysis of variance (ANOVA)
was used to compare means among more than two groups; differences were considered statistically
significant when p < 0.05. For animal survival, statistical analysis was performed with GraphPad
Prism software using Log-rank (Mantel-Cox) test.
5. Conclusions
In this work, through a stepwise approach we describe a novel formulation for a DC cancer
vaccine with both in vitro an in vivo improved efficacy in a mouse model, compared to canonical DC
vaccine preparations that were previously available and largely in use in the field. The encouraging
results here presented in the context of ovarian cancer also support future work aimed at translating
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this approach in the clinic, especially in combination with other adjuvant immunotherapy (such as
checkpoint blockades) to further improve therapeutic outcomes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/1/40/s1,
Figure S1: Example of the gating strategy for DCs and for the surface marker CD86, Figure S2: DCs matured with
a two-step protocol in the presence of anti-CD40 and anti-IL10R antibodies for 24 h, followed by LPS/IFNγ/CpG
stimulate a more Th1-skewed T cell response compared to canonical LPS/IFNγ maturation.
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